Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
25 August 2009 - 11:15PM
PR Newswire (US)
JERUSALEM, August 25 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com/), a
developer of oral delivery systems, today announced that it is the
recipient of the 2009 Frost & Sullivan European Oral Drug
Delivery Technology Innovation Award. Oramed Pharmaceuticals is
developing a platform technology to create oral delivery systems
for drugs and vaccines delivered via injection. Oramed focuses on
the treatment of diabetes through its proprietary flagship product,
an Oral Insulin capsule that is currently in Phase 2b clinical
trials. Oramed's research pipeline also includes other product
candidates, such as an Oral GLP-1 Analog capsule. "We are honored
to receive the 2009 European Oral Drug Delivery Technology
Innovation Award," said Nadav Kidron, Esq., Oramed's CEO. "Being
recognized for our leadership position in the oral drug delivery
field by Frost & Sullivan is an encouraging validation of our
progress. Frost & Sullivan's Technology Innovation Awards
recognize companies in a variety of regional and global markets for
demonstrating outstanding achievement and superior performance in
areas such as leadership, technological innovation, customer
service and strategic product development. Industry analysts
compare market participants and measure performance through
in-depth interviews, analysis and extensive secondary research in
order to identify best practices in the industry. About Frost &
Sullivan Frost & Sullivan, the Growth Partnership Company,
partners with clients to accelerate their growth. The company's
TEAM Research, Growth Consulting and Growth Team Membership(TM)
empower clients to create a growth-focused culture that generates,
evaluates and implements effective growth strategies. Frost &
Sullivan employs over 45 years of experience in partnering with
Global 1000 companies, emerging businesses and the investment
community from more than 30 offices on six continents. For more
information about Frost & Sullivan's Growth Partnerships, visit
http://www.frost.com/. About Oramed Pharmaceuticals Oramed
Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters
are based in Jerusalem. For more information, please visit
http://www.oramed.com/ Forward-looking statements Some of the
statements contained in this press release are forward-looking
statements which involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the company, or industry results, to be materially
different from any future results, performance or achievements
expressed or implied by such forward looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development
and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results,
performance or achievements of the company to differ materially
from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any
forward-looking statements. Company and Investor Relations Contact:
Oramed Pharmaceuticals Tara Horn USA: +1-646-240-4193
Int'l:+972-54-334-4318 Email: DATASOURCE: Oramed Pharmaceuticals
Inc. CONTACT: Company and Investor Relations Contact: Oramed
Pharmaceuticals, Tara Horn, USA: +1-646-240-4193,
Int'l:+972-54-334-4318, Email:
Copyright